Northwestern University Feinberg School of Medicine
Dr Leventhal is a Professor of Surgery and Director of the Kidney Transplant Program and Associate Director of the Pancreas Transplant Program at Northwestern University. His research interests include developing cell-based therapies to achieve tolerance induction in solid organ transplant recipients.
Post-transplant maintenance care with chronic immunosuppression is necessary to prevent graft rejection; however, it imposes significant burdens on patients and the healthcare system alike. This highlights the unmet need for a therapeutic option with the goal of improving both long-term patient and graft survival, as well as quality-of-life outcomes.
A new, innovative approach to post–kidney transplant care utilizes FCR001, an investigational allogeneic cell therapy, to establish durable chimerism and drug-free immune tolerance in living-donor kidney transplant recipients across all degrees of human leukocyte antigen (HLA)-mismatch.
An expert panel will lead a discussion around the clinical consequences associated with the conventional, chronic immunosuppressive therapy utilized as standard of care post-transplant, the need for innovation and improved long-term outcomes in kidney transplant, as well as the potential of harnessing the power of induced tolerance with FCR001.
The Transplantation Society
740 Notre-Dame Ouest
Montréal, QC, H3C 3X6